List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Overview
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Companies Involved in Therapeutics Development
Amryt Pharma plc
Crinetics Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Ipsen SA
Progenics Pharmaceuticals Inc
Strongbridge Biopharma plc
Takeda Pharmaceutical Co Ltd
Zucara Therapeutics Inc
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Drug Profiles
AP-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRN-00808 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRN-01941 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Edotreotide Labeled Yttrium 90 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanreotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanreotide SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize SSTR2 and SSTR4 for Chronic Pain and Neuropathic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize SSTR2 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veldoreotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veldoreotide MR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Dormant Products
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Discontinued Products
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Product Development Milestones
Featured News & Press Releases
Jun 21, 2018: Crinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Acromegaly
Mar 12, 2018: Crinetics Pharmaceuticals Announces Upcoming Presentation on Acromegaly Drug Candiadate CRN00808 at ENDO 2018
Feb 13, 2018: Health Canada approves Ipsen Somatuline Auto gel for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumors (NETs)
Feb 08, 2018: Zucara Therapeutics Receives Funding to Advance Lead Drug Candidate
Jan 15, 2018: Ipsen To Present Abstracts On lanreotide ASCO Gastrointestinal Symposium 2018
Oct 26, 2017: Crinetics Pharmaceuticals Initiates Phase 1 Study of Lead Candidate CRN00808 for Acromegaly
Sep 21, 2017: JDRF Funds Zucara Therapeutics' Approach to Preventing Hypoglycemia in People with Type 1 Diabetes
Sep 18, 2017: U.S. FDA Approves New Indication for Ipsen's Somatuline Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Sep 04, 2017: Ipsen To Present Data on Somatuline at European Society of Medical Oncology congress
Jul 13, 2017: Crinetics Pharmaceuticals Awarded $2.8 Million SBIR Grant to Support Development of Acromegaly Drug Candidate CRN00808
Jul 03, 2017: Somatuline Auto gel 120 mg receives Japanese approval for a new indication for the treatment of gastro-entero-pancreatic neuroendocrine tumors
Jun 01, 2017: Ipsen To Present New Data of Lanreotide at ASCO
Mar 09, 2017: Ipsen announces data presentation on lanreotide (Somatuline Auto gel) at the European Neuroendocrine Tumor Society (ENETS) 2017 conference
Feb 06, 2017: Amryt Pharma Announces positive pre-clinical study results for drug compound with potential to treat acromegaly, AP102
Dec 02, 2016: Amryt Pharma provides update on AP-102
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Amryt Pharma plc, H2 2018
Pipeline by Crinetics Pharmaceuticals Inc, H2 2018
Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2018
Pipeline by Ipsen SA, H2 2018
Pipeline by Progenics Pharmaceuticals Inc, H2 2018
Pipeline by Strongbridge Biopharma plc, H2 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Pipeline by Zucara Therapeutics Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Discontinued Products, H2 2018

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Companies Mentioned
• Amryt Pharma plc
• Crinetics Pharmaceuticals Inc
• Daewoong Pharmaceutical Co Ltd
• Ipsen SA
• Progenics Pharmaceuticals Inc
• Strongbridge Biopharma plc
• Takeda Pharmaceutical Co Ltd
• Zucara Therapeutics Inc